AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
15 mai 2018 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has reached a long-term...
AXIM Biotech Announces Successful Completion of Pre-IND Meeting with FDA on Comparable Product to Marinol; Green Light from FDA for IND Submission
12 déc. 2017 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), a world leader in cannabinoid research and development, announced today that it has successfully completed a...
Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep Disorders
07 nov. 2017 09h00 HE
|
CURE Pharmaceutical; Therapix Biosciences Ltd.
OXNARD, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology announced today that it has entered into a product...
AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study
19 juin 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...
AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.gov
15 mai 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, May 15, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that information on the...
AXIM Biotech Enters Term Sheet Agreement With US API Company to Develop Bioequivalent Product to Marinol
28 mars 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that it...